NCT03359356View on ClinicalTrials.gov

Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 9, 2018

Primary Completion Date

January 14, 2020

Study Completion Date

December 17, 2020

Conditions
Alopecia Areata
Interventions
DRUG

Dupilumab

A total of 24 doses

DRUG

Placebo

A total of 24 doses

Trial Locations (2)

10029

Icahn School of Medicine at Mount Sinai, New York

10065-6399

The Rockefeller University Laboratory for Investigative Dermatology, New York

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Rockefeller University

OTHER

collaborator

Regeneron Pharmaceuticals

INDUSTRY

collaborator

Sanofi

INDUSTRY

lead

Icahn School of Medicine at Mount Sinai

OTHER

NCT03359356 - Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD) | Biotech Hunter | Biotech Hunter